Gills JJ - Search Results

1

Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells.

Zhang C, Elkahloun AG, Liao H, Delaney S, Saber B, Morrow B, Prendergast GC, Hollander MC, Gills JJ, Dennis PA. Zhang C, et al. Among authors: gills jj. Mol Cancer Ther. 2011 Jul;10(7):1137-48. doi: 10.1158/1535-7163.MCT-10-1028. Epub 2011 May 6. Mol Cancer Ther. 2011. PMID: 21551261 Free PMC article.

2

Targeting aberrant signal transduction pathways in lung cancer.

Gills JJ, Granville CA, Dennis PA. Gills JJ, et al. Cancer Biol Ther. 2004 Feb;3(2):147-55. doi: 10.4161/cbt.3.2.612. Epub 2004 Feb 1. Cancer Biol Ther. 2004. PMID: 14764993 Review.

3

The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt.

Gills JJ, Dennis PA. Gills JJ, et al. Expert Opin Investig Drugs. 2004 Jul;13(7):787-97. doi: 10.1517/13543784.13.7.787. Expert Opin Investig Drugs. 2004. PMID: 15212619 Review.

4

Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells.

Tsurutani J, Castillo SS, Brognard J, Granville CA, Zhang C, Gills JJ, Sayyah J, Dennis PA. Tsurutani J, et al. Among authors: gills jj. Carcinogenesis. 2005 Jul;26(7):1182-95. doi: 10.1093/carcin/bgi072. Epub 2005 Mar 24. Carcinogenesis. 2005. PMID: 15790591

5

Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.

Tsurutani J, West KA, Sayyah J, Gills JJ, Dennis PA. Tsurutani J, et al. Among authors: gills jj. Cancer Res. 2005 Sep 15;65(18):8423-32. doi: 10.1158/0008-5472.CAN-05-0058. Cancer Res. 2005. PMID: 16166321

6

Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway.

Granville CA, Memmott RM, Gills JJ, Dennis PA. Granville CA, et al. Among authors: gills jj. Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):679-89. doi: 10.1158/1078-0432.CCR-05-1654. Clin Cancer Res. 2006. PMID: 16467077 Review.

7

Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt.

Gills JJ, Holbeck S, Hollingshead M, Hewitt SM, Kozikowski AP, Dennis PA. Gills JJ, et al. Mol Cancer Ther. 2006 Mar;5(3):713-22. doi: 10.1158/1535-7163.MCT-05-0484. Mol Cancer Ther. 2006. PMID: 16546986

8

Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38alpha, through MKK3/6-independent and -dependent mechanisms.

Gills JJ, Castillo SS, Zhang C, Petukhov PA, Memmott RM, Hollingshead M, Warfel N, Han J, Kozikowski AP, Dennis PA. Gills JJ, et al. J Biol Chem. 2007 Sep 14;282(37):27020-27029. doi: 10.1074/jbc.M701108200. Epub 2007 Jul 13. J Biol Chem. 2007. PMID: 17631503 Free article.

9

Targeting Akt in cancer therapy.

LoPiccolo J, Granville CA, Gills JJ, Dennis PA. LoPiccolo J, et al. Among authors: gills jj. Anticancer Drugs. 2007 Sep;18(8):861-74. doi: 10.1097/CAD.0b013e3280cc2c6f. Anticancer Drugs. 2007. PMID: 17667591 Review.

10

Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.

Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, Hollander MC, Kawabata S, Tsokos M, Figg WD, Steeg PS, Dennis PA. Gills JJ, et al. Clin Cancer Res. 2007 Sep 1;13(17):5183-94. doi: 10.1158/1078-0432.CCR-07-0161. Clin Cancer Res. 2007. PMID: 17785575

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

42 results

Search Page